PE20120592A1 - Metodo con biomarcadores para el seguimiento de un tratamiento - Google Patents

Metodo con biomarcadores para el seguimiento de un tratamiento

Info

Publication number
PE20120592A1
PE20120592A1 PE2011001619A PE2011001619A PE20120592A1 PE 20120592 A1 PE20120592 A1 PE 20120592A1 PE 2011001619 A PE2011001619 A PE 2011001619A PE 2011001619 A PE2011001619 A PE 2011001619A PE 20120592 A1 PE20120592 A1 PE 20120592A1
Authority
PE
Peru
Prior art keywords
treatment
disease
biomarker
biomarkers
monitoring
Prior art date
Application number
PE2011001619A
Other languages
English (en)
Spanish (es)
Inventor
Tokuzo Arao
Kanae Kudo
Kazuhiko Nakagawa
Kazuto Nishio
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120592(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20120592A1 publication Critical patent/PE20120592A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2011001619A 2009-03-12 2010-03-11 Metodo con biomarcadores para el seguimiento de un tratamiento PE20120592A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12

Publications (1)

Publication Number Publication Date
PE20120592A1 true PE20120592A1 (es) 2012-06-09

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001619A PE20120592A1 (es) 2009-03-12 2010-03-11 Metodo con biomarcadores para el seguimiento de un tratamiento

Country Status (24)

Country Link
US (1) US8802384B2 (enExample)
EP (1) EP2406628A1 (enExample)
JP (1) JP5667581B2 (enExample)
KR (1) KR20110137307A (enExample)
CN (1) CN102334030A (enExample)
AR (1) AR076113A1 (enExample)
AU (1) AU2010223256B2 (enExample)
BR (1) BRPI1011688A2 (enExample)
CA (1) CA2755055A1 (enExample)
CL (1) CL2011002260A1 (enExample)
CO (1) CO6430497A2 (enExample)
EA (1) EA201101300A1 (enExample)
EC (1) ECSP11011323A (enExample)
IL (1) IL214747A0 (enExample)
MA (1) MA33120B1 (enExample)
MX (1) MX2011009482A (enExample)
NZ (1) NZ594843A (enExample)
PE (1) PE20120592A1 (enExample)
SG (1) SG174324A1 (enExample)
TN (1) TN2011000457A1 (enExample)
TW (1) TW201100802A (enExample)
UA (1) UA107789C2 (enExample)
UY (1) UY32482A (enExample)
WO (1) WO2010103058A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
NO2299987T3 (enExample) * 2008-06-06 2018-07-21
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2018081236A1 (en) * 2016-10-28 2018-05-03 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2008103B1 (en) 2006-04-18 2010-07-28 Wellstat Biologics Corporation Detection of circulating endothelial cells
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
CN101512017A (zh) * 2006-09-07 2009-08-19 阿斯利康(瑞典)有限公司 评价用靶向ret受体酪氨酸激酶的药物治疗的患者的方法
EP2527467A3 (en) 2007-04-13 2013-03-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
US20100184049A1 (en) 2007-04-27 2010-07-22 Steve Goodison Glycoprotein Profiling of Bladder Cancer

Also Published As

Publication number Publication date
AR076113A1 (es) 2011-05-18
JP5667581B2 (ja) 2015-02-12
NZ594843A (en) 2014-03-28
UY32482A (es) 2010-10-29
EP2406628A1 (en) 2012-01-18
BRPI1011688A2 (pt) 2016-03-22
AU2010223256B2 (en) 2014-08-21
JP2012520446A (ja) 2012-09-06
ECSP11011323A (es) 2011-10-31
MA33120B1 (fr) 2012-03-01
WO2010103058A1 (en) 2010-09-16
CO6430497A2 (es) 2012-04-30
IL214747A0 (en) 2011-11-30
TN2011000457A1 (en) 2013-03-27
MX2011009482A (es) 2011-09-27
SG174324A1 (en) 2011-10-28
AU2010223256A1 (en) 2011-09-15
TW201100802A (en) 2011-01-01
CL2011002260A1 (es) 2012-03-23
CN102334030A (zh) 2012-01-25
US8802384B2 (en) 2014-08-12
US20100233705A1 (en) 2010-09-16
KR20110137307A (ko) 2011-12-22
CA2755055A1 (en) 2010-09-16
EA201101300A1 (ru) 2012-04-30
UA107789C2 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
MX2012004619A (es) Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.
ATE554389T1 (de) Apex als marker für lungenkrebs
CR20110567A (es) Dispositivos para diagnostico y metodos relacionados
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
EA201370063A1 (ru) Фосфолипидом рака
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
MX380526B (es) Desarrollo y uso de sondas fluorescentes de bilirrubina sin enlazar
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
ES2845150T3 (es) Diagnóstico de pancreatitis aguda (PA) mediante la detección de glicoproteína 2 isoforma alfa (GP2A)
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
EP2074427A4 (en) Diagnostic biomolecule(s)
PE20160657A1 (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto
MX380889B (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson.
AR105379A1 (es) Dispositivo para detectar proteínas mal plegadas y sus métodos de uso
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
ATE508364T1 (de) Diagnoseverfahren für präeklampsie
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome

Legal Events

Date Code Title Description
FC Refusal